<DOC>
	<DOCNO>NCT02798419</DOCNO>
	<brief_summary>DFD05 vs. Active01 treatment common wart</brief_summary>
	<brief_title>Active-Controlled Study Assess Efficacy Safety DFD-05 Subjects With Common Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>1 . Subjects , gender race , must good general health determine Investigator clinical diagnosis common wart . 2 . Subjects must least 1 visible , discrete , common wart least 3 mm longitudinal diameter hand , foot ( exclude sol ) palm ( order priority ) . 3 . The wart must present least past 12 week , 3 year 4 . Subjects must agree use study product use wartremoving product ( prescription , OTC occlusion ) course study . 5 . Subjects must free systemic dermatologic disorder , opinion Investigator , interfere study result . 6 . Female subject childbearing potential must agree use contraception study . All woman childbearing potential must negative urine pregnancy test Screening Baseline 4 , 8 &amp; 12 week visit . 7 . Subjects physically able apply study product affect area obtain help . 1 . Women pregnant nursing planning become pregnant study . 2 . Subjects treat wart within 30 day prior Baseline Visit ( e.g . salicylic acid , azelaic acid , cryotherapy ) . 3 . Subjects participate trial involve investigational product 30 day prior Baseline Visit . 4 . Subjects chronic active liver disease , renal impairment , cutaneous systemic lupus erythematosus , autoimmune disorder , immunosuppression , disease medical condition would interfere study place subject unacceptable risk , determine investigator . 5 . Subjects immunosuppressive agent would impact immune response e.g . cyclosporine , mycophenolate mofetil , azathioprine , etc . 6 . Subjects use use local/systemic steroid immunosuppressive medication within 30 day prior Baseline Visit . 7 . Subjects use use systemic topical retinoids within 30 day prior Baseline Visit . 8 . Subjects unable comply study requirement . 9 . Subjects skin disease like molluscum contagiosum may confound evaluation common wart . 10 . Subjects receive treatment type cancer within 5 year Baseline Visit , except skin cancer cervical cancer ( situ ) allow least 1 year Baseline Visit . 11 . Subjects unable comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>